The Federal Trade Commission on Friday filed a lawsuit over insulin prices against the three largest pharmaceutical middlemen that negotiate prescription drug prices, arguing that the companies artificially inflate the costs of the lifesaving diabetes drug for patients.
The suit targets the three largest pharmacy benefits managers: UnitedHealth Group’s OptumRx, CVS Health’s Caremark, and Cigna’s Express Scripts.
Real journalism.Trusted by millions.
Unlimited access to in-depth reporting, expert analysis, and the stories that shape our country.
Subscribe Now
Already a member? Log in
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.